Belarus
Tuberculosis profile
| High MDR-TB burden |
Population  2012 9.4 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.57 (0.51–0.63) 6 (5.4–6.7)
Mortality (HIV+TB only) 0.073 (0.058–0.086) 0.77 (0.62–0.91)
Prevalence  (includes HIV+TB) 10 (4.7–18) 108 (50–188)
Incidence  (includes HIV+TB) 6.6 (5.4–8) 70 (57–85)
Incidence (HIV+TB only) 0.28 (0.23–0.34) 3 (2.4–3.6)
Case detection, all forms (%) 72 (60–89)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 277 (33) Relapse 941 (67)
Smear-negative 2 184 (57) Treatment after failure 209 (15)
Smear-unknown / not done     Treatment after default 27 (2)
Extrapulmonary 381 (10) Other 227 (16)
Other          
Total new 3 842   Total retreatment 1 404  
           
Other (history unknown)          
Total new and relapse 4 783   Total cases notified 5 246  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 3.1 2.3 1.1
Age < 15 1 8 12
Laboratories 2012
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 15.4
Drug susceptibility testing (per 5 million population) 4.3
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 60   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 79  
Retreatment 29  
TB/HIV 2012 Number (%)
TB patients with known HIV status 5 246 (100)
HIV-positive TB patients 229 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 153 (67)
HIV-positive people screened for TB 7 895  
HIV-positive people provided with IPT 258  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 35 (33–37) 69 (66–71)
MDR-TB cases among notified pulmonary
TB cases
1 200 (1 100–1 300) 960 (920–1 000)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 2 164 (90%) 1 183 (84%) 3 347
Laboratory-confirmed MDR-TB cases 753 811 1 604
Patients started on MDR-TB treatment     2 478
Financing TB control 2013
National TB programme budget (US$ millions) 19
% Funded domestically 26%
% Funded internationally 24%
% Unfunded 50%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data